ONC (BeOne Medicines Ltd. American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by ONC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Titus B. Ball | Principal Accounting Officer | Sell | — | — |
| 2026-08-27 | Xiaobin Wu | President and COO | Sell | — | — |
| 2026-08-13 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-08-12 | JOHN OYLER | Chief Executive Officer | Sell | — | — |
| 2026-08-05 | Aaron Rosenberg | Chief Financial Officer | Sell | — | — |
| 2026-08-03 | Chan Henry Lee | SVP, General Counsel | Sell | — | — |
| 2026-07-24 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-07-22 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-07-17 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-07-17 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-07-14 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-07-14 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-07-10 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-06-25 | Xiaobin Wu | President and COO | Sell | — | — |
| 2026-06-25 | Lai Wang | President, Global Head of R&D | Sell | — | — |
| 2026-06-25 | JOHN OYLER | Chief Executive Officer | Sell | — | — |
| 2026-06-18 | Xiaobin Wu | President and COO | Sell | — | — |
| 2026-06-18 | Chan Henry Lee | SVP, General Counsel | Sell | — | — |
| 2026-06-18 | JOHN OYLER | Chief Executive Officer | Sell | — | — |
| 2026-06-18 | Lai Wang | President, Global Head of R&D | Sell | — | — |
| 2026-06-15 | OLIVIER BRANDICOURT | Director | A | — | — |
| 2026-06-15 | Alessandro Riva | Director | A | — | — |
| 2026-06-15 | Margaret Dugan | Director | A | — | — |
| 2026-06-15 | Elizabeth Fisher Mooney | Director | A | — | — |
| 2026-06-15 | Lai Wang | President, Global Head of R&D | MIXED | — | — |
| 2026-06-15 | Charles Lazelle Sawyers | Director | A | — | — |
| 2026-06-15 | Shalini Sharp | Director | A | — | — |
| 2026-06-15 | Xiaobin Wu | President and COO | MIXED | — | — |
| 2026-06-15 | Xiaodong Wang | Director | A | — | — |
| 2026-06-15 | Titus B. Ball | Principal Accounting Officer | MIXED | — | — |
| 2026-06-15 | Aaron Rosenberg | Chief Financial Officer | MIXED | — | — |
| 2026-06-15 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-06-15 | JULIAN BAKER | Director | A | — | — |
| 2026-06-15 | JOHN OYLER | Chief Executive Officer | MIXED | — | — |
| 2026-06-15 | ANTHONY C HOOPER | Director | A | — | — |
| 2026-06-10 | Chan Henry Lee | SVP, General Counsel | Sell | — | — |
| 2026-06-10 | Titus B. Ball | Principal Accounting Officer | Sell | — | — |
| 2026-06-10 | Xiaobin Wu | President and COO | Sell | — | — |
| 2026-06-10 | JOHN OYLER | Chief Executive Officer | Sell | — | — |
| 2026-06-10 | Lai Wang | President, Global Head of R&D | Sell | — | — |
| 2026-06-03 | Qingqing Yi | Director | Sell | — | — |
| 2026-05-27 | Margaret Dugan | Director | Sell | — | — |
| 2026-05-27 | Corazon (Corsee) D. Sanders | Director | Sell | — | — |
| 2026-05-27 | Alessandro Riva | Director | Sell | — | — |
| 2026-05-27 | 667, L.P. | Director | Sell | — | — |
| 2026-05-15 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-04-10 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-03-13 | Chan Henry Lee | SVP, General Counsel | MIXED | — | — |
| 2026-03-10 | Aaron Rosenberg | Chief Financial Officer | A | — | — |
| 2026-03-10 | Chan Henry Lee | SVP, General Counsel | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 28,239,116 | — |
| — | Director | 8,635,593 | — |
| — | Director | 730,643 | — |
| — | Director | 730,643 | — |
| — | President, Global Head of R&D | 601,965 | — |
| — | Director | 161,551 | — |
| — | Principal Accounting Officer | 97,929 | — |
| — | Director | 83,720 | — |
| — | Director | 73,164 | — |
| — | Director | 73,164 | — |
| — | Director | 54,470 | — |
| — | Director | 46,306 | — |
| — | Director | 24,271 | — |
| — | Director | 18,980 | — |
| — | President and COO | 16,365 | — |
| — | SVP, General Counsel | 2,666 | — |
| — | Director | 1,946 | — |
| — | Director | 9 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ONC quote page; the site-wide leaderboard is on the insider transactions hub.